Monday, 1 July 2013

Implications of the Human Microbiome on Pharmaceutical Microbiology


With the establishment of the Human Microbiome Project, our knowledge of the diverse span of microbial species within and across the human body has been significantly enhanced, revealing valuable insight into community niche specialization, genetic diversity, and the prevalence of indigenous opportunistic pathogens.

The human microbiome (or human microbiota) is the aggregate of microorganisms, a microbiome that resides on the surface and in deep layers of skin, in the saliva and oral mucosa, in the conjunctiva, and in the gastrointestinal tracts. They include bacteria, fungi, and archaea.

Most of the microbes associated with humans appear to be not harmful at all, but rather assist in maintaining processes necessary for a healthy body. Moreover, at specific sites on the body, a different set of microbes may perform the same function for different people.

A new article of interest, examining the implications of the Human Microbiome Project, on various facets of pharmaceutical microbiology, has been published by the American Pharmaceutical Review. The article has been written by Cara Wilder, Tim Sandle and Scott Sutton.



The article can be viewed on-line at: APR.



Posted by Tim Sandle